Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Geriatrics
Published in: BMC Geriatrics 1/2017

Open Access 01-12-2017 | Research Article

Prevalence and risk factors for depression and anxiety in Chinese patients with Parkinson disease

Authors: Shi-Shuang Cui, Juan-Juan Du, Rao Fu, Yi-Qi Lin, Pei Huang, Ya-Chao He, Chao Gao, Hua-Long Wang, Sheng-Di Chen

Published in: BMC Geriatrics | Issue 1/2017

Login to get access

Abstract

Background

Anxiety and depression are common in Parkinson disease and both are important determinants of quality of life in patients. Several risk factors are identified but few research have investigated general and Parkinson’s disease (PD)-specific factors comprehensively. The aim of this work was to explore PD-specific and -non-specific risk factors for PD with depression or anxiety.

Methods

A cross-sectional survey was performed in 403 patients with PD. Multivariate logistic analysis was used to investigate the prevalence and risk factors for the depression and anxiety in PD. The data of patients included demographic information, medicine history, disease duration, age at onset (AAO), family history, anti-parkinsonism drug, modified Hoehn and Yahr staging (H-Y) stage, scales of motor and non-motor symptoms and substantia nigra (SN) echogenic areas.

Results

403 PD patients were recruited in the study. Depression and anxiety were present in 11.17% and 25.81% respectively. Marital status, tumor, higher Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) II score, dyskinesia, higher Hamilton Anxiety Rating Scale (HARS) score and lower the Parkinson’s disease sleep scale (PDSS) score were associated with depression in PD. female gender, higher rapid eye movement behavior disorder Questionnaire-Hong Kong (RBD-HK) score, higher Hamilton Deprssion Rating Scale (HAMD) score, higher the scale for outcomes in PD for autonomic symptoms (SCOPA-AUT)score and larger SN echogenic areas were associated with anxiety. Neither depression nor anxiety was related to any anti-parkinsonism drugs.

Conclusions

The prevalence of depression and anxiety in the current PD patients was 11.17% and 25.81% respectively. Disease of tumor, currently having no partner, severer motor function, dyskinesia, poorer sleep quality and anxiety were risk factors for PD with depression. Female, depression, rapid eye movement behavior disorder (RBD), autonomic dysfunction and larger SN area were risk factors for PD with anxiety.
Literature
1.
Broen MP, Narayen NE, Kuijf ML, Dissanayaka NN, Leentjens AF. Prevalence of anxiety in Parkinson's disease: a systematic review and meta-analysis. Mov Disord. 2016;31(8):1125–33.CrossRefPubMed
2.
Reijnders JS, Ehrt U, Weber WE, Aarsland D, Leentjens AF. A systematic review of prevalence studies of depression in Parkinson's disease. Mov Disord. 2008;23(2):183–9. quiz 313CrossRefPubMed
3.
A S: Quality of life and depression in Parkinson’s disease. J Neurol Sci 2006, 2006(248):151–157.
4.
Dissanayaka NN, Sellbach A, Matheson S, O'Sullivan JD, Silburn PA, Byrne GJ, Marsh R, Mellick GD. Anxiety disorders in Parkinson's disease: prevalence and risk factors. Mov Disord. 2010;25(7):838–45.CrossRefPubMed
5.
Becker C, Brobert GP, Johansson S, Jick SS, Meier CR. Risk of incident depression in patients with Parkinson disease in the UK. Eur J Neurol. 2011;18(3):448–53.CrossRefPubMed
6.
Dissanayaka NN, Sellbach A, Silburn PA, O'Sullivan JD, Marsh R, Mellick GD. Factors associated with depression in Parkinson's disease. J Affect Disord. 2011;132(1–2):82–8.CrossRefPubMed
7.
Riedel O, Heuser I, Klotsche J, Dodel R, Wittchen HU, Group GS. Occurrence risk and structure of depression in Parkinson disease with and without dementia: results from the GEPAD study. J Geriatr Psychiatry Neurol. 2010;23(1):27–34.CrossRefPubMed
8.
LeentjensAFG L, Verhey FRJ: markers for depression in Parkinson’s disease. Acta Psychiatr Scand 2002, 106:196–201.
9.
Pontone GM. Anxiety in Parkinson's: a complex syndrome of non-dopaminergic and dopaminergic etiology. Eur J Neurol. 2017;24(4):541–2.CrossRefPubMed
10.
Sagna A, Gallo JJ, Pontone GM. Systematic review of factors associated with depression and anxiety disorders among older adults with Parkinson's disease. Parkinsonism Relat Disord. 2014;20(7):708–15.CrossRefPubMedPubMedCentral
11.
Broen MP, Kohler S, Moonen AJ, Kuijf ML, Dujardin K, Marsh L, Richard IH, Starkstein SE, Martinez-Martin P, Leentjens AF. Modeling anxiety in Parkinson's disease. Mov Disord. 2016;31(3):310–6.CrossRefPubMed
12.
Leentjens AF, Dujardin K, Marsh L, Martinez-Martin P, Richard IH, Starkstein SE. Symptomatology and markers of anxiety disorders in Parkinson's disease: a cross-sectional study. Mov Disord. 2011;26(3):484–92.CrossRefPubMed
13.
14.
Zhang Z-X, Roman GC, Hong Z, C-B W, Q-M Q, Huang J-B, Zhou B, Geng Z-P, J-X W, Wen H-B, et al. Parkinson's disease in China: prevalence in Beijing, Xian, and shanghai. Lancet. 2005;365(9459):595–7.CrossRefPubMed
15.
16.
Li N, Chen G, Zeng P, Pang J, Gong H, Han Y, Zhang Y, Zhang E, Zhang T, Zheng X. Prevalence of depression and its associated factors among Chinese elderly people: a comparison study between community-based population and hospitalized population. Psychiatry Res. 2016;243:87–91.CrossRefPubMed
17.
Kang HJ, Bae KY, Kim SW, Shin IS, Yoon JS, Kim JM. Anxiety symptoms in Korean elderly individuals: a two-year longitudinal community study. Int Psychogeriatr. 2016;28(3):423–33.CrossRefPubMed
18.
Leentjens AF1 MA, Dujardin K, Marsh L, Martinez-Martin P, Richard IH, Starkstein SE, Köhler S.: Modeling depression in Parkinson disease Disease-specific and nonspecific risk factors. Neurology 2013 Sep, 17(81(12)):1036–1043.
19.
Garlovsky JK, Overton PG, Simpson J. Psychological predictors of anxiety and depression in Parkinson's disease: a systematic review. J Clin Psychol. 2016;72(10):979–98.CrossRefPubMed
20.
Burn DJ, Landau S, Hindle JV, Samuel M, Wilson KC, Hurt CS, Brown RG. Group P-PS: Parkinson's disease motor subtypes and mood. Mov Disord. 2012;27(3):379–86.CrossRefPubMed
21.
Negre-Pages L, Grandjean H, Lapeyre-Mestre M, Montastruc JL, Fourrier A, Lepine JP, Rascol O, DoPaMi PSG. Anxious and depressive symptoms in Parkinson's disease: the French cross-sectionnal DoPaMiP study. Mov Disord. 2010;25(2):157–66.CrossRefPubMed
22.
CG G. New developments in depression, anxiety, compulsiveness, and hallucinations in Parkinson’s disease. Mov Disord. 2010;25(Suppl 1):S104–9.
23.
Remy P, Doder M, Lees A, Turjanski N, Brooks D. Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain. 2005;128(Pt 6):1314–22.CrossRefPubMed
24.
M. Stacy HM, K. Kroenke: Responsiveness of motor and nonmotor symptoms of Parkinson's disease to dopaminergic therapy. Prog Neuropsychopharmacol Biol Psychiatr 2010, 34:57–61.
25.
Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, Obeso J, Marek K, Litvan I, Lang AE, et al. MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord. 2015;30(12):1591–601.CrossRefPubMed
26.
Martinez-Martin P, Leentjens AF, De Pedro-cuesta J, Chaudhuri KR, Schrag AE, Weintraub D: accuracy of screening instruments for detection of neuropsychiatric syndromes in Parkinson's disease. Mov Disord 2016, 31(3):270–279.
27.
Anette Schrag M. PhD, Paolo Barone, MD, Richard G. Brown, PhD, Albert F.G. Leentjens, MD, PhD, William M. McDonald, MD, Sergio Starkstein, MD, Daniel Weintraub, MD, Werner Poewe, MD, Olivier Rascol, MD, Cristina Sampaio, MD, Glenn T. Stebbins, PhD, and Christopher G. Goetz, MD: depression rating scales in Parkinson’s disease: critique and recommendations. Mov Disord. 2007;22(8):1077–92.CrossRefPubMedPubMedCentral
28.
Hu G, Bidel S, Jousilahti P, Antikainen R, Tuomilehto J. Coffee and tea consumption and the risk of Parkinson's disease. Mov Disord. 2007;22(15):2242–8.CrossRefPubMed
29.
Khera AV, Emdin CA, Drake I, Natarajan P, Bick AG, Cook NR, Chasman DI, Baber U, Mehran R, Rader DJ, et al. Genetic risk, adherence to a healthy lifestyle, and coronary disease. N Engl J Med. 2016;375(24):2349–58.CrossRefPubMedPubMedCentral
30.
Tan LC, Koh WP, Yuan JM, Wang R, WL A, Tan JH, Tan EK, MC Y. Differential effects of black versus green tea on risk of Parkinson's disease in the Singapore Chinese health study. Am J Epidemiol. 2008;167(5):553–60.CrossRefPubMed
31.
Ragonese P, Salemi G, Morgante L, Aridon P, Epifanio A, Buffa D, Scoppa F, Savettieri G, Case-Control Study A. On cigarette, alcohol, and coffee consumption preceding Parkinson’s disease. Neuroepidemiology. 2003;22(5):297–304.CrossRefPubMed
32.
Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord. 2010;25(15):2649–53.CrossRefPubMed
33.
Chen WKW, Chen S, Wang Y, Xiao Q, Wang G, Liu J, Chen SD. Hyposmia correlates with SNCA variant and non-motor symptoms in Chinese patients with Parkinson's disease. Parkinsonism Relat Disord. 2015;21(6):610–4.CrossRefPubMed
34.
Zhou HY, Sun Q, Tan YY, YY H, Zhan WW, Li DH, Wang Y, Xiao Q, Liu J, Chen SD. Substantia nigra echogenicity correlated with clinical features of Parkinson's disease. Parkinsonism Relat Disord. 2016;24:28–33.CrossRefPubMed
35.
Rutten S, van der Ven PM, Weintraub D, Pontone GM, Leentjens AFG, Berendse HW, van der Werf YD, van den Heuvel OA. Predictors of anxiety in early-stage Parkinson's disease - results from the first two years of a prospective cohort study. Parkinsonism Relat Disord. 2017;
36.
Baxter AJ, Charlson FJ, Cheng HG, Shidhaye R, Ferrari AJ, Whiteford HA. Prevalence of mental, neurological, and substance use disorders in China and India: a systematic analysis. The Lancet Psychiatry. 2016;3(9):832–41.CrossRefPubMed
37.
Dan X, Wang C, Zhang J, Gu Z, Zhou Y, Ma J, Chan P. Association between common genetic risk variants and depression in Parkinson's disease: a dPD study in Chinese. Parkinsonism Relat Disord. 2016;33:122–6.CrossRefPubMed
38.
Fan JY, Chang BL, Wu YR. Relationships among depression, anxiety, sleep, and quality of life in patients with Parkinson's disease in Taiwan. Parkinsons Dis. 2016;2016:4040185.PubMedPubMedCentral
39.
Landau S, Harris V, Burn DJ, Hindle JV, Hurt CS, Samuel M, Wilson KC, Brown RG. Anxiety and anxious-depression in Parkinson's disease over a 4-year period: a latent transition analysis. Psychol Med. 2016;46(3):657–67.CrossRefPubMed
40.
Rutten S, Ghielen I, Vriend C, Hoogendoorn AW, Berendse HW, Leentjens AF, van der Werf YD, Smit JH, van den Heuvel OA. Anxiety in Parkinson's disease: symptom dimensions and overlap with depression and autonomic failure. Parkinsonism Relat Disord. 2015;21(3):189–93.CrossRefPubMed
41.
Qureshi SU, Amspoker AB, Calleo JS, Kunik ME, Marsh L. Anxiety disorders, physical illnesses, and health care utilization in older male veterans with Parkinson disease and comorbid depression. J Geriatr Psychiatry Neurol. 2012;25(4):233–9.CrossRefPubMed
42.
Braam AW, Copeland JR, Delespaul PA, Beekman AT, Como A, Dewey M, Fichter M, Holwerda TJ, Lawlor BA, Lobo A, et al. Depression, subthreshold depression and comorbid anxiety symptoms in older Europeans: results from the EURODEP concerted action. J Affect Disord. 2014;155:266–72.CrossRefPubMed
43.
Mitchell AJCM, Bhatti H, Halton M, Grassi L, Johansen C, Meader N. Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies. Lancet Oncol. 2011;12(2):160–74.CrossRefPubMed
44.
Linden W1 VA, Mackenzie R, Greig D.: Anxiety and depression after cancer diagnosis: prevalence rates by cancer type, gender, and age. J Affect Disord 2012, 10(2–3):343–351.
45.
Hubert M, Wichowicz JS. Mirosława Derejko, Wiesław Jerzy Cubała: factors associated with depression in Parkinson’s disease- a cross-sectional study in a polish population. European Psychiatry. 2006;21:516–20.CrossRef
46.
Schrag AJM, Quinn NP. What contributes to depression in Parkinson's disease? Psychol Med. 2001;31:65–73.CrossRefPubMed
47.
Lauterbach ECSK. Differential correlates of mood and cognition in dystonia and Parkinson’s disease. Mov Disord. 2002;17(suppl 5):S223.
48.
Fidalgo C, Ko WK, Tronci E, Li Q, Stancampiano R, Chuan Q, Bezard E, Carta M. Effect of serotonin transporter blockade on L-DOPA-induced dyskinesia in animal models of Parkinson's disease. Neuroscience. 2015;298:389–96.CrossRefPubMed
49.
Warren Olanow C, Kieburtz K, Rascol O, Poewe W, Schapira AH, Emre M, Nissinen H, Leinonen M, Stocchi F. Stalevo reduction in dyskinesia evaluation in Parkinson's disease I: factors predictive of the development of levodopa-induced dyskinesia and wearing-off in Parkinson's disease. Mov Disord. 2013;28(8):1064–71.CrossRefPubMed
50.
Suzuki K, Miyamoto M, Miyamoto T, Okuma Y, Hattori N, Kamei S, Yoshii F, Utsumi H, Iwasaki Y, Iijima M, et al. Correlation between depressive symptoms and nocturnal disturbances in Japanese patients with Parkinson's disease. Parkinsonism Relat Disord. 2009;15(1):15–9.CrossRefPubMed
51.
52.
Martinez-Martin P, Falup Pecurariu C, Odin P, van Hilten JJ, Antonini A, Rojo-Abuin JM, Borges V, Trenkwalder C, Aarsland D, Brooks DJ, et al. Gender-related differences in the burden of non-motor symptoms in Parkinson's disease. J Neurol. 2012;259(8):1639–47.CrossRefPubMed
53.
Zhu K, van Hilten JJ, Marinus J. Onset and evolution of anxiety in Parkinson's disease. Eur J Neurol. 2017;24(2):404–11.CrossRefPubMed
54.
Jiang SM, Yuan YS, Tong Q, Zhang L, QR X, Ding J, Zhang KZ. The association between clinically relevant anxiety and other non-motor symptoms in Parkinson's disease. Neurol Sci. 2015;36(11):2105–9.CrossRefPubMed
55.
Kalk NJND, Lingford-Hughes AR. The role of central noradrenergic dysregulation in anxiety disorders: evidence from clinical studies. J Psychopharmacol. 2011;25:3.CrossRefPubMed
56.
De Luka SRSM, Pekmezović T, Milovanović B, Kostić VS. When do the symptoms of autonomic nervous system malfunction appear in patients with Parkinson’s disease? Vojnosanit Pregl. 2014;71:346–51.CrossRefPubMed
57.
Rolinski M, Szewczyk-Krolikowski K, Tomlinson PR, Nithi K, Talbot K, Ben-Shlomo Y, MT H. REM sleep behaviour disorder is associated with worse quality of life and other non-motor features in early Parkinson's disease. J Neurol Neurosurg Psychiatry. 2014;85(5):560–6.CrossRefPubMed
58.
Boeve BF, Silber MH, Saper CB, Ferman TJ, Dickson DW, Parisi JE, Benarroch EE, Ahlskog JE, Smith GE, Caselli RC, et al. Pathophysiology of REM sleep behaviour disorder and relevance to neurodegenerative disease. Brain. 2007;130(Pt 11):2770–88.CrossRefPubMed
59.
60.
Pellegrino RM, Boda E, Montarolo F, Boero M, Mezzanotte M, Saglio G, Buffo A, Roetto A. Transferrin receptor 2 dependent alterations of brain iron metabolism affect anxiety circuits in the mouse. Sci Rep. 2016;6:30725.CrossRefPubMedPubMedCentral
61.
Berg DGC, Rausch WD, Mäurer M, Wesemann W, Riederer P, Becker G. Iron accumulation in the substantia nigra in rats visualized by ultrasound. Ultrasound Med Biol. 1999;25(6):901–4.CrossRefPubMed
62.
Zhu K, van Hilten JJ, Marinus J. Associated and predictive factors of depressive symptoms in patients with Parkinson's disease. J Neurol. 2016;263(6):1215–25.CrossRefPubMedPubMedCentral
63.
Tong Q, Zhang L, Yuan Y, Jiang S, Zhang R, Xu Q, Ding J, Li D, Zhou X, Zhang K. Reduced plasma serotonin and 5-hydroxyindoleacetic acid levels in Parkinson's disease are associated with nonmotor symptoms. Parkinsonism Relat Disord. 2015;21(8):882–7.CrossRefPubMed
64.
65.
Wee N, Kandiah N, Acharyya S, Chander RJ, Ng A, WL A, Tan LC. Depression and anxiety are co-morbid but dissociable in mild Parkinson's disease: a prospective longitudinal study of patterns and predictors. Parkinsonism Relat Disord. 2016;23:50–6.CrossRefPubMed
66.
Leentjens AF, Dujardin K, Marsh L, Martinez-Martin P, Richard IH, Starkstein SE, Weintraub D, Sampaio C, Poewe W, Rascol O, et al. Anxiety rating scales in Parkinson's disease: critique and recommendations. Mov Disord. 2008;23(14):2015–25.CrossRefPubMed
Metadata
Title
Prevalence and risk factors for depression and anxiety in Chinese patients with Parkinson disease
Authors
Shi-Shuang Cui
Juan-Juan Du
Rao Fu
Yi-Qi Lin
Pei Huang
Ya-Chao He
Chao Gao
Hua-Long Wang
Sheng-Di Chen
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Geriatrics / Issue 1/2017
Electronic ISSN: 1471-2318
DOI
https://doi.org/10.1186/s12877-017-0666-2

Other articles of this Issue 1/2017

BMC Geriatrics 1/2017 Go to the issue

Research Article

How does washing without water perform compared to the traditional bed bath: a systematic review

Case report

A 95 year-old suffering circulatory arrest after accidental hypothermia: a case report

Research Article

Exploring residents’ experiences of mealtimes in care homes: A qualitative interview study

Research Article

Rest-activity rhythms in small scale homelike care and traditional care for residents with dementia

Research Article

Assessing the predictive power of psychological empowerment and health literacy for older patients’ participation in health care: a cross-sectional population-based study

Research Article

Trajectories of Life Satisfaction and their Predictors among Korean Older Adults
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits